Nexalin Technology, Inc. · NASDAQ:NXL
Nexalin Technology — Investor Presentation (June 2024)
35 slides from Nexalin Technology's investor presentation, June 2024
Slide 1: Investor Presentation June 2024
Investor Presentation June 2024
Slide 2: Nexalin Forward Looking Statement
Nexalin Forward Looking Statement This presentation material includes forward-looking statements that reflect our current views with respect to future events. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking sta
Slide 3: Company Snapshot
Company Snapshot Our mission at Nexalin Technology is to design and market FDA Class II & III neuro-stimulators for the treatment of: Anxiety – Depression - Insomnia – Dementia - Addiction 3 issued Large 40+ units in $40M invested $94B addressable patents and 6 $40M use globally since inception mark
Slide 4: Investment Highlights
Investment Highlights Approved treatment indications: • FDA: Anxiety, Insomnia and Depression (Gen-1) • NMPA (China FDA): Depression and Insomnia (Gen-2) Innovative Digital Near-Term Growth Tele-Med Advantage Treatment with Virtual Nexalin’s Gen-3 medical Nexalin will introduce at- Digital Distribut
Slide 5: The Global Mental Health Epidemic
The Global Mental Health Epidemic Insomnia Anxiety Alzheimer’s Addiction Depression 40 million Americans An estimated 31.1% There are over 55 284 million people World Health Organization suffer from chronic of adults experience million people aged 15-64 used (WHO) reports 280 million insomnia. Some
Slide 6: Large and Growing Treatment Markets
Large and Growing Treatment Markets Everyone Likely Knows Someone That Needs Help >35% #1 Of reporting adults in Depression is the $210.5 Billion the US have leading cause of Lost earnings per year experienced short sleep disability in the US due to serious mental duration (< 7 hours).2 among ages 1
Slide 7: Target Market
Target Market - 6 out of 10 people in need of mental health care will not receive it 1 - Those that do receive care, are usually given medication 58% <50% 75% of patients remission rate of participants experience for the most across studies moderately severe common prefer a non-drug side effects2 me
Slide 8: Industry Approach
Industry Approach Current treatment options for common mental health illnesses present more obstacles than solutions for the patient Handheld - tDCS (internet) Pharmaceutical - Drugs & Pills Transcranial Magnetic Stimulation rTMS • Low Efficacy (<2 mA) • Low Efficacy • Low Efficacy • Unregulated usa
Slide 9: Nexalin Approach
Nexalin Approach • High efficacy (4 -15 mA) Features and Benefits • Regulated • Low Risk Profile – 4/15 milliamps (safe) • Safe • Non-Invasive (low ancillary needs) • Nonaddictive • 77.5 htz Frequency (proprietary) • Supported by solid clinical data • Symmetric Square Wave (no voltage) • Disrupts de
Slide 10: Technology Evolution
Technology Evolution 2021 Q2 2021 Q2 2020 Q1 Nexalin Gen-2 China A,D,I Nexalin Gen-1 China NMPA approves Nexalin for Nexalin develops the Nexalin begins Gen-2 prototype treatment of Depression and analyzing 510K medical device and Insomnia application process begins research with for Anxiety and new
Slide 11: Halo Clarity | The Future
Halo Clarity | The Future • Unchanged proprietary technical features • 77.5 Hz @15 milliamps • Unchanged clinical efficacy • FDA Premarket De Novo application • State of the art design and electronics • Home and office Use (removes stigma associated with receiving HALO Clarity Headset mental health
Slide 12: Global Funded Clinical Trial Partnerships
Global Funded Clinical Trial Partnerships Drive acceptance through trials, key opinion leaders and direct sales 12
Slide 13: Clinical Trial Results
Clinical Trial Results Nexalin Technology providers report 75% of patients treated have over 70% improvement and 90% had over 50% improvement of their reported symptoms 1 2 NEXALIN TECHNOLOGY CLINICS ANXIETY DEPRESSION INSOMNIA Diagnosed Average Improvement 77% 74% 84% 1. Insomnia Clinical Trial -Ef
Slide 14: Clinical Trial Results | Insomnia
Clinical Trial Results | Insomnia Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Clinical Trial Insomnia Adjusted Response Rate Insomnia Adjust Remission Rate 90.0% 60.0% 77.2% 50% 80.0% 50.0% 70.0% 60.0% 53.4% 40.0% 36.6% 50.0% 30.0% 40.0% 20.0% 30.0% 19.9% 20.0% 13.4% 16.7% 20.0% 10.
Slide 15: Clinical Trial Results | Depression
Clinical Trial Results | Depression Preliminary Depression Randomized Study Pilot Depression Randomized Study Depression Response Rate after 4 weeks Depression Remission Rate 100% 93% 70.0% 63.3% 60.0% 55.1% 80% 50.0% 40.0% 60% Active 28.3% 30.0% 19.6% 40% 33% Sham 20.0% 10.0% 20% 0.0% 4 weeks 8 wee
Slide 16: Clinical Trial Results | Recent Studies
Clinical Trial Results | Recent Studies Preliminary Treatment Resistant Depression Study Preliminary Addiction Randomized Study (30 Active and 30 Sham) Treatment Resistant Depression 30.0 26.4 Changes in Visual Analogue Scale (VAS) 25.0 Craving Score HAMD-17 total Score 30 26.9 20.0 Visual Analog Sc
Slide 17: Clinical Trial Results | TBI/PTSD (combat related)
Clinical Trial Results | TBI/PTSD (combat related) MEG Source Imaging Reveals Neuronal Changes in Combat-related Mild Traumatic Brain Injury after Transcranial Electrical Stimulation using Nexalin Objectives: Results: • Veterans in the active treatment group showed significant • To understand the ne
Slide 18: Nexalin Growth Strategy
Nexalin Growth Strategy Virtual Clinic US Expanding Department Indications Of Defense Global Expansion 18
Slide 19: Virtual Clinic
Virtual Clinic Nexalin Technology: Nexalin promotes and manages the physician/patient relationship in on-line portal Patients: Physicians: Receive evaluation and Physicians prescribe, treatment in privacy of home. monitor and evaluate Treatment is monitored by the treatment compliance and physician
Slide 20: Expanding Indications
Expanding Indications 2022 2031-32 Anxiety and Depression1 $11.5B $16B Insomnia2 $3.8B $6.4B Alzheimer’s and Dementia3 $5.1B $9.7 Substance Use Disorder4 (SUD) $35.1B $60.1B Opiate Addiction5 $3.3B $6.1B Concussion / TBI / PTSD6 $3.3B $7.2B Chronic Pain7 $69.1 $140B 1. Future Market Insights – FMI 2
Slide 21: Global Expansion
Global Expansion • Joint Venture (JV) formed in Hong Kong to advance the Asia Pacific distribution • Nexalin ADI (Gen-2) approved by China NMPA in 2021 • JV has funded, conducted and published 6 clinicals studies to date • Research performed in leading global psychiatric centers in Asia (funded by J
Slide 22: US Department of Defense Partnership
US Department of Defense Partnership • Goals 1. Develop multisite veterans’ study for TBI/PTSD 2. To become a primary contractor 2-stage distribution • Veterans Hospital System (VA) • Active duty / Combat Theatre • Actions taken • Nexalin America division created to deal with US Gov’t (Dept of Defen
Slide 23: Revenue Creation | Gen-2 & Gen-3
Revenue Creation | Gen-2 & Gen-3 • Chinese distributor is currently selling Gen-2 ADI Nexalin devices in China • The Company will sell the Gen-2 and Gen-3 ADI Nexalin device to physicians (providers) in the USA • Recurring Revenue | Nexalin Gen-2 ADI device requires single use disposable electrode •
Slide 24: Financial Snapshot as of March 31, 2024
Financial Snapshot as of March 31, 2024 Cash & Short Term Investments $2.1M Debt $0 Common Shares Outstanding 7.4M Fully Diluted Shares Outstanding 12.3M Warrants Outstanding 2.6M Management/Director Ownership 28% 24
Slide 25: Milestones
Milestones 2024 Jan Mar May Jul Sep Nov 2025 Mar May Jul Sep Nov 2025 Oman MoH Oman MoH Approval of Nexalin ADI Approval Brazil ANVISA Approval of Nexalin ADI Brazil Approval Delivery of 200 HALOs for Pilot Clinical Studies Manufacturing Completion of Anxiety & Insomnia Pilot Clinical Studies Comple
Slide 26: Executive Management Team
Executive Management Team Mark White --- David Owens M.D. --- Michael Nketiah --- Marilyn Elson --- Sr VP - Quality, Regulatory, President and Chief Executive Controller Chief Medical Officer Officer Clinical Ms. Elson has been a Certified Dr. Owens brings extensive Mr. White leads the executive tea
Slide 27: Advisory Board
Advisory Board John Patrick Claude – Engineering and Product Development (Co-Founder / waveform designer) Mr. John Claude, in conjunction with Dr. Yakov Katsnelson, designed and developed the original tACS waveform that is marketed as Nexalin Technology. John now leads all engineering, research and
Slide 28: Appendix
Appendix 28
Slide 29: Intellectual Property | Patents
Intellectual Property | Patents 29
Slide 30: Intellectual Property | Patents
Intellectual Property | Patents 30
Slide 31: Intellectual Property | Patents
Intellectual Property | Patents 31
Slide 32: Intellectual Property | Patents
Intellectual Property | Patents 32
Slide 33: Intellectual Property | Patents
Intellectual Property | Patents 33
Slide 34: Intellectual Property | Patents
Intellectual Property | Patents 34
Slide 35: Thank You
Thank You
Nexalin Technology — Investor Presentation (June 2024) on 6ix